Skip to main content

PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview

  • PaxMedica Chairman and CEO Howard Weisman participated in a recent Bell2Bell Podcast interview and was joined by Buzz Woods from Corporate Communications
  • Weisman discussed the company’s strategy to seek FDA approval for Suramin as a treatment for Human African Trypanosomiasis (“HAT”) and plans for 2024
  • If PaxMedica is successful in getting approval in HAT, the company believes that could lead to the receipt of a Priority Review Voucher (“PRV”)
  • The company hopes to monetize the PRV to raise funds that will support research and future trials investigating Suramin as a treatment for Autism Spectrum Disorder
  • PaxMedica hopes to file an investigational new drug application to use Suramin in a large-scale trial in the U.S. in 2024

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company specializing in innovative treatments for unmet needs in neurodevelopmental disorders, has recently introduced a groundbreaking regulatory strategy that could potentially pave the way for the approval of its lead product candidate, Suramin, in the United States. During a recent episode of the Bell2Bell (“B2B”) Podcast, Chairman and CEO Howard Weisman, along with Buzz Woods from Corporate Communications, delved into this strategy.

To hear the interview, please visit…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.